Non-Hodgkin Lymphoma | Specialty

FDA Halts Enrollment on Tazemetostat Trials

April 24th 2018

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.

Dr. Leslie Discusses Duvelisib in Follicular Lymphoma

April 9th 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the role of duvelisib (IPI-145) in the treatment of patients with follicular lymphoma.

Expert Discusses Developments in Follicular Lymphoma

April 9th 2018

Lori Ann Leslie, MD, provides expert insight on the latest developments in the field of follicular lymphoma.

EBRT Effective in Relapsed/Refractory Follicular Lymphoma

March 30th 2018

Findings from a small, retrospective study showed that external beam radiation therapy induced an overall response rate of 86% in patients with relapsed/refractory follicular lymphoma.

Dr. Winter Discusses the ZUMA-7 Trial in DLBCL

March 27th 2018

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the ZUMA-7 trial (NCT03391466) in diffuse large B-cell lymphoma (DLBCL).

Dr. Leslie Discusses 2017 ASH Annual Meeting Updates

March 27th 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses trial updates for patients with follicular lymphoma in the maintenance setting, which were presented at the 2017 ASH Annual Meeting.

Gene Expression Model Predicts PFS in Follicular Lymphoma

February 28th 2018

A “robust” 23-gene expression-based model successfully predicted progression-free survival for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.

Dr. Locke Discusses the Impact of the ZUMA-1 Trial in NHL

February 14th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses the impact of the ZUMA-1 trial for patients with non-Hodgkin Lymphoma (NHL).

Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL

February 7th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Dr. Skarbnik on Impact of Checkpoint Inhibition Following ASCT

January 30th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.

Liso-Cel Highly Active in Relapsed/Refractory DLBCL

January 30th 2018

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.

Advances and Research Needs in Lymphoma

January 26th 2018

Investigating CAR T-Cell Therapy in Lymphoma

January 26th 2018

Approval of Acalabrutinib in Mantle Cell Lymphoma

January 26th 2018

Duration of Rituximab Maintenance in FL

January 26th 2018

Long-Term Data With Copanlisib in Follicular Lymphoma

January 26th 2018

Follicular Lymphoma: Obinutuzumab and Chemotherapy

January 26th 2018

MAVORIC Trial in Cutaneous T-Cell Lymphoma

January 26th 2018

Primary Cutaneous T-cell Lymphoma: ALCANZA Trial

January 26th 2018

Role of Novel Therapies in Hodgkin Lymphoma

January 26th 2018